The COVID-19 Payer Pulse Survey

Posted by Ed Schoonveld on Mon, Apr 27, 2020

Many of our clients have been asking us about the impact of COVID-19 on coverage approvals and the management of prescription drugs. We used our rapid response PayerLIVE survey instrument to get some reactions from U.S., EU and Canadian payers with respect to the impact of COVID-19 on their functioning, pharma industry relationships and expectations for the near future.


>
Read More

What could be in store for the value and access landscape?

Posted by Richard Secker-Johnson on Tue, Apr 07, 2020

While the immediate impact of coronavirus on the pharmaceutical industry is evident, one area of uncertainty is how the virus will alter the landscape for the pricing and access of medicines in the longer term. Much of this impact will likely be linked to the macroeconomic effects of coronavirus, where we can speculate that changes in the size of economies as well as reprioritization of healthcare spending may alter payers’ ability and willingness to pay for medicines overall, and also for certain diseases and classes of medicine. However, another significant factor could be the impact of the virus on the value and access policy landscape. While there’s still uncertainty around how these policy changes could develop, we can look to some of the immediate global reactions to coronavirus that may serve as leading indicators of potential mid- to longer-term policy change.


>
Read More

The Price (or Lack) of Global Health

Posted by Ed Schoonveld on Fri, Dec 20, 2019

Governments, private health insurers and employers worldwide are deeply concerned about the increasing cost of healthcare. U.S. healthcare cost as a share of GDP has nearly tripled from 1970 to 2017, resulting in a growing societal burden.


>
Read More

Global Prescription Drug Costs: Why We Need Differential Pricing

Posted by Ed Schoonveld on Wed, Dec 18, 2019

The Trump administration is not the first government to explore the use of international price referencing to force drug prices down. This usually involves the institution of a price ceiling based on an average price for the same drug in a “basket” of other countries. The basket is supposed to consist of countries with similar income levels, but oftentimes that’s not actually the case. That’s just one of the many problems with international price referencing laws.


>
Read More

Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Dec 16, 2019

Dean Hakanson co-wrote this blog post with Ed Schoonveld.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More